Рак поджелудочной железы список литературы
Генератор титульных листовТаблица истинности ONLINE |
|
© 2009-2020, Список Литературы |
Источник
1. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview.//Nat Rev Gastroenterol Hepatol. – 2009 – V. 6, N 12. – P. 699 – 708.
2. Wolpin BM, Ng K, Bao Y, Kraft P, Stampfer MJ et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer.//Cancer Epidemiol Biomarkers Prev. – 2012. – V. 21, N 1. – P. 82 – 91
3. Duell EJ, Lucenteforte E, Olson SH et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4).//Ann Oncol. – 2012. – V. 23, N 11. – P. 2964 – 70.
4. Huang Y, Cai X, Qiu M et al. Prediabetes and the risk of cancer: a meta-analysis.//Diabetologia. – 2014. – V. 57, N 11. – P. 2261 – 9.
5. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г./М.: Издательская группа РОНЦ, 2014. – 226 с.
6. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study.//J Clin Oncol. – 2011. – V. 29. – P. 3457 – 3465
7. Tempero M., Malafa M., Al-Hawary M. et al. NCCN Clinical practice guidelines in oncology. Pancreatic adenocarcinoma. V. 2.2016./Published online https://www.nccn.org/professionals/physician_gls/f_guidelines.asp (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
8. Li JH, He R, Li YM et al. Endoscopic ultrasonography for tumor node staging and vascular invasion in pancreatic cancer: a meta-analysis. Dig Surg. – 2014. – V. 31, N 4 – 5. – P. 297 – 305 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
9. Agarwal B, Abu-Hamda E, Molke KL et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer.//Am J Gastroenterol. – 2004. – 99, N 5. – P. 844 – 50. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
10. Wyse JM, Carone M, Paquin SC et al. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer.//J Clin Oncol. – 2011. – V. 29, N 26. – P. 3541 – 6 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
11. Farma JM, Santillan AA, Melis M et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.//Ann Surg Oncol. – 2008. – V. 15, N 9. – P. 2465 – 71. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
12. Daly M., Pilarski R., Berry M. et al. NCCN Clinical practice guidelines in oncology. Genetic/familial high-risk assessment: breast and ovarian. V. 2. 2017/Published online (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp) https://www.nccn.org/professionals/physician_gls/f_guidelines. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
13. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial.//JAMA – 2007. – N 297. – P. 267 – 277 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
14. Патютко Ю.И., Кудашкин Н.Е., Котельников А.Г. Гепатопанкреатодуоденальная резекция – есть ли перспективы?//Хирургия. Журнал им. Н.И. Пирогова. – 2011. – N 8. – С. 41 – 46. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
15. Патютко Ю.И., Кудашкин Н.Е., Поляков А.Н., Абиров К.А., Подлужный Д.В. Проксимальная и дистальная резекция поджелудочной железы с сохранением тела.//Хирургия. Журнал им. Н.И. Пирогова. – 2012. – N 2 – С. 70 – 73. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
16. Патютко Ю.И., Котельников А.Г., Кудашкин Н.Е., Агафонова М.Г. Резекция сосудов в хирургии рака поджелудочной железы.///Вестник хирургической гастроэнтерологии. – 2012. – N 3 – с. 21 – 32 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
17. Varadhachary G.R., Tamm E.P., Abbruzzese J.L. et al. Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy.//Annals of Surgical Oncology. – 2006. – V. 13, N 8. – P. 1035 – 1046. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
18. Патютко Ю.И., Кудашкин Н.Е., Котельников А.Г., Чистякова О.В. Тотальная панкреатэктомия при опухолевом поражении поджелудочной железы.//Хирургия. Журнал им. Н.И. Пирогова. – 2016. – N 9 – С. 13 – 20 (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
19. Базин И.С., Покатаев И.А., Попова А.С. и соавт. Место химиотерапии в лечении локализованного рака поджелудочной железы//Злокачественные опухоли. – 2016. – Т. 21, N 4 (спецвыпуск 1). – С. 20 – 25. (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
20. Massucco P, (https://www.ncbi.nlm.nih.gov/pubmed/? term=Massucco%20P%5BAuthor%5D&cauthor=true&cauthor_uid=16955382)Capussotti L, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Capussotti%20L%5BAuthor%5D&cauthor=true&cauthor_uid=16955382)Magnino A et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Magnino%20A%5BAuthor%5D&cauthor=true&cauthor_uid=16955382)Ann Surg Oncol. – 2006. – V. 13, 9. – P. 1201 – 8. (https://www.ncbi.nlm.nih.gov/pubmed/16955382)
21. Liao WC1, (https://www.ncbi.nlm.nih.gov/pubmed/? term=Liao%20WC%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)Chien KL, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Chien%20KL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)Lin YL et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis.//Lancet Oncol. – 2013. – V. 14, N 11. – P. 1095 – 103. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lin%20YL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)
22. Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014 Feb 20; 32(6): 504 – 12 (https://www.ncbi.nlm.nih.gov/pubmed/? term=Lin%20YL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)
23. Neoptolemos J.P., Moore M.J., Cox T.F. et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11; 308(2): 147 – 56. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lin%20YL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)
24. Neoptolemos J., Palmer D., Ghaneh P. et al. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 34, 2016 (suppl; abstr LBA4006) (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lin%20YL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)
25. Покатаев И.А., Тюляндин С.А. Системная лекарственная терапия метастатического рака поджелудочной железы. – Современная онкология. – 2016. – N 1. – С. 20 – 24. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lin%20YL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)
26. Burris HA 3rd, Moore MJ, Andersen J et al. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Lin%20YL%5BAuthor%5D&cauthor=true&cauthor_uid=24035532)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.//J Clin Oncol. – 1997 – V. 15, N 6. – P. 2403 – 13. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)
27. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.//N Engl J Med. – 2011. – V. 364, 19. – P. 1817 – 25. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)
28. Von Hoff D., Ervin T., Arena F. et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine.//N Engl J Med – 2013. V. 369. – P. 1691 – 703. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)
29. Fogelman D., Sugar E.A., Oliver G. et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.//Cancer Chemother Pharmacol. – 2015. – V. 76, N 3. – P. 489 – 98. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)
30. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.//J Clin Oncol. – 2007 – V. 25, N 15. – P. 1960 – 6. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)
31. Boeck S, Wilkowski R, Bruns CJ, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.//Oncology – 2007. – N. 73. – P. 221 – 7. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)
32. Novarino A, Satolli MA, Chiappino I, et al. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.//Am J Clin Oncol – 2009. – V. 32. – P. 44 – 8 (https://www.ncbi.nlm.nih.gov/pubmed/9196156)
33. Xiong HQ, Varadhachary GR, Blais JC, et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.//Cancer – 2008. – N 113. – P. 2046 – 52 (https://www.ncbi.nlm.nih.gov/pubmed/9196156)
34. Neuzillet C, Hentic O, Rousseau B, et al. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemctabine and platinum-salts.//World J Gastroenterol – 2012. – N 18. – P. 4533 – 41 (https://www.ncbi.nlm.nih.gov/pubmed/9196156)
35. Van der Gaag NA, Rauws EA, van Eijck CH et al. Preoperative biliary drainage for cancer of the head of the pancreas.//N Engl J Med – 2010. – N 362. – P. 129 – 137 (https://www.ncbi.nlm.nih.gov/pubmed/9196156)
36. Кудашкин Н.Е., Агафонова М.Г., Котельников А.Г., Патютко Ю.И. Стратегия радикального лечения опухолей периампулярной локализации, осложненных механической желтухой.//Фарматека. – 2012. – N 8(241) – С. 7781. (https://www.ncbi.nlm.nih.gov/pubmed/9196156)
37. Maire F1, Hammel P, Ponsot P et al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas.//Am J Gastroenterol. – 2006. – V. 101, N 4. – P. 735 – 42. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Maire%20F%5BAuthor%5D&cauthor=true&cauthor_uid=16635221)
38. Jeurnink SM, Steyerberg EW, Hof Gv et al. Gastrojejunostomy versus stent placement in patients with malignant gastric outlet obstruction: a comparison in 95 patients.//J Surg Oncol. – 2007. – V. 96, N 5. – P. 389 – 96. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Maire%20F%5BAuthor%5D&cauthor=true&cauthor_uid=16635221)
39. Wong GY, Schroeder DR, Carns PE et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial.//JAMA. – 2004. – V. 291, N 9. – P. 1092 – 9. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Maire%20F%5BAuthor%5D&cauthor=true&cauthor_uid=16635221) (https://www.ncbi.nlm.nih.gov/pubmed/?term=Maire%20F%5BAuthor%5D&cauthor=true&cauthor_uid=16635221) (https://www.ncbi.nlm.nih.gov/pubmed/?term=Maire%20F%5BAuthor%5D&cauthor=true&cauthor_uid=16635221)
Источник
Генератор титульных листовТаблица истинности ONLINE |
|
Источник